CD19 and diffuse large B-cell lymphoma: CD19-targeted CAR-T cell therapy has demonstrated significant efficacy and reasonable safety in patients with R/R diffusive LBCL (DLBCL), high-grade B-cell lymphoma (HGBCL), DLBCL arising from transformed follicular lymphoma (tFL), and primary mediastinal B-cell lymphoma (PMBCL) [24–28].